TRex Bio
South San Francisco, California, United States · Biotechnology, Health Care, Therapeutics
TRexBio is a discovery stage biotechnology company leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us to identify and characterize novel targets for therap
Key facts
- Headquarters
- South San Francisco, California, United States
- Employees
- 62
- Industries
- Biotechnology, Health Care, Therapeutics
- Status
- Public (TRXB)
- Website
- trex.bio
- Company page
Recent activity at TRex Bio
- : TRexBio raises $50 million to advance its immunology pipeline, led by investors including Janus Henderson and Balyasny Asset Management.
- : TRex Holdings
- : TRex Bio, Inc. raised $84 million in a Series B round led by Delos Capital to advance its immunology programs into clinical development.
- : Trexbio Closes The Final Tranche Of $59 Million Series A Financing To Advance Innovation In Tissue Immunobiology For The Treatment Of Cancer And Inflammatory Diseases
TRex Bio funding history
| Date | Round | Amount |
|---|---|---|
| Jan 2026 | Funding Round | $50.0M |
| Nov 2024 | Venture | $42.3M |
| Nov 2024 | Series B | $84.0M |
| Jun 2021 | Series A | $59.0M |
Leadership
- Laura Berner, Chief Operating Officer
- Johnston Erwin, Chief Executive Officer
Verified email and direct lines for TRex Bio’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
TRex Bio in the news
- TRex Bio raised $116.7 million in a U.S. IPO, pricing at the bottom of its range - Quartz (Oct 09, 2026)
- Retension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues - Reuters (Sep 18, 2026)
- Retension, Lilly-backed TRex both plan to join IPO stampede - Fierce Biotech (Sep 21, 2026)
- TRex Bio, Clinical-Stage Immunology Biopharma, Files for Nasdaq Global Select Market IPO - TradingView (Oct 09, 2026)
- TRex Bio gets USD 50m Series B support for Deep Biology platform - AllSci (Jan 27, 2026)
- In test of investors' appetite, Lilly-connected TRex Bio plots $153 million IPO - The Business Journals (Oct 05, 2026)
- TRexBio Closes $50 Million Financing to Support a Growing Clinical-Stage Immunology Pipeline of Tissue-Targeted Treg Therapeutics - Business Wire (Jan 27, 2026)
- TRXB Stock Price and Chart — NASDAQ:TRXB - TradingView (Sep 23, 2026)
Companies similar to TRex Bio
- BridgeBio Oncology Therapeutics · Biotechnology, Health Care, Therapeutics
- Zai Lab Limited & MediLink Therapeutics (Suzhou) Ltd · Biotechnology, Health Care, Therapeutics
- Franklin Biolabs · Biotechnology, Health Care, Therapeutics
- Valerio Therapeutics S.A · Biotechnology, Health Care, Therapeutics
- AvenCell Therapeutics · Biotechnology, Health Care, Therapeutics
About TRex Bio: questions and answers
What does TRex Bio do?
TRexBio is a discovery stage biotechnology company leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us to identify and characterize novel targets for therap
Where is TRex Bio headquartered?
TRex Bio is headquartered in South San Francisco, California, United States.
How many employees does TRex Bio have?
TRex Bio has about 62 employees.
Has TRex Bio raised funding?
Yes. Fundz has recorded 4 funding events for TRex Bio. The most recent, Funding Round of $50.0M, was in Jan 2026.
Who leads TRex Bio?
Johnston Erwin is a Chief Executive Officer at TRex Bio.
What is the latest news on TRex Bio?
On Jan 27, 2026, TRexBio raises $50 million to advance its immunology pipeline, led by investors including Janus Henderson and Balyasny Asset Management.
Is TRex Bio a public company?
Yes. TRex Bio is publicly traded under the ticker TRXB.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy